摘要
目的探讨前列腺癌组织中肺癌转移相关基因(LCMR1)表达与临床病理的关系及临床预后的意义。方法采用免疫组化S-P法检测60例前列腺癌组织、癌旁组织和30例前列腺增生组织LCMR1的表达情况,并应用统计学方法对LCMR1的表达情况与临床资料、病理参数及生存预后进行分析。结果LCMR1在前列腺癌组织、癌旁组织和前列腺增生组织的阳性表达率分别为51.7%、8.3%、6.7%,三者表达差异具有统计学意义(P<0.0001)。LCMR1在前列腺癌组织中的表达与Gleason评分、TNM分期、切缘阳性率、淋巴结转移情况相关(P<0.05),与年龄、PSA无相关性(P>0.05),其高表达与无生化复发生存率显著负相关(P<0.05),COX比例风险模型结果表明Gleason评分(HR=3.194,P=0.013)及手术切缘阳性(HR=19.946,P<0.0001)是前列腺癌患者生化复发的独立预后影响因素。LCMR1表达不能独立预测生化复发危险性(HR=1.710,P=0.191)。结论LCMR1的上调表达与前列腺癌的恶性程度及早期诊断相关。
Objective To examine differences in Lung Cancer Metastasis-Related Protein(LCMR1)expression in prostate cancer(PCa)tissue using immunohistochemistry,and analyze correlations between LCMR1 expression and associated clinical data and pathological stage of PCa in an attempt to explore the significance of LCMR1 expression in the pathogenesis.Methods immunohistochemical S-P method was conducted to analyze the expression of LCMR1 in 60 PCa samples and 30 benign prostate hyperplasia(BPH)samples.Correlations between the intensity of LCMR1 expression and the clinical data,pathological stage and survival prediction were analyzed statistically.Results The positive rate of LCMR1 expression in PCa,paracancerous and BHP tissues was 51.7%,8.3%and 6.7%respectively,there was a significant difference in LCMR1 expression between the three tissue groups(P<0.0001).LCMR1 expression in PCa tissue increased proportionally with the increase of clinicopathological stage,there was a significant difference(P<0.05),but that was not correlated with Gleason score,Age and sex(P>0.05).Moreover,Kaplan-Meier survival analysis showed that the higher expression of LCMR1 was correlated with shorter biochemical recurrence-free survival,while COX multivariate logistic regression analysis showed that only Gleason score(HR=3.194,P=0.013)and SM(HR=19.946,P<0.0001)were independent prognostic factors for biochemical recurrence-free survival(P<0.05),and LCMR1 was not an independent factor for prediction of prognosis(HR=1.710,P=0.191).Conclusion Our data suggests that the up-regulation of LCMR1 is associated with PCa’s malignant degree and early diagnosis.
作者
李勋钢
张文圣
邓新喜
卢依刚
万滨
张卓
LI Xungang;ZHANG Wensheng;DENG Xinxi(Department of Urologic Surgery,First People’s Hospital of Jiujiang,Affiliated medical school of Nanchang University,Jiujiang,Jiangxi 332000,China)
出处
《江西医药》
CAS
2021年第8期1096-1099,1104,共5页
Jiangxi Medical Journal
基金
江西省卫生健康委科技计划,编号SKJP220202346。
关键词
LCMR1
前列腺癌
免疫组化
前列腺增生
LCMR1
prostate cancer
immunohistochemistry
prostatic hyperplasia
